CASI Pharmaceuticals Inc
CASI0.810USD
-0.021-2.59%
收盘 12/19, 16:00（美东）报价延迟15分钟
12.55M总市值
亏损市盈率 TTM
关于 CASI Pharmaceuticals Inc 公司
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
CASI Pharmaceuticals Inc简介
公司代码CASI
公司名称CASI Pharmaceuticals Inc
上市日期Aug 23, 2021
CEOHe (Wei-Wu)
员工数量233
证券类型Ordinary Share
年结日Aug 23
公司地址1701-1702, China Central Office Tower 1
城市BEIJING
上市交易所NASDAQ OMX - NASDAQ BASIC
国家China
邮编100025
电话861065618789
网址https://www.casipharmaceuticals.com/
公司代码CASI
上市日期Aug 23, 2021
CEOHe (Wei-Wu)
CASI Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Mr. Wei (Larry) Zhang, Ph.D.
Mr. Wei (Larry) Zhang, Ph.D.
Senior Vice President
Senior Vice President
--
--
Ms. Chunhua Wang
Ms. Chunhua Wang
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Rui Zhang
Mr. Rui Zhang
Investor Relations
Investor Relations
--
--
Mr. Huang Hai
Mr. Huang Hai
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月19日 周五
更新时间: 12月19日 周五
持股股东
股东类型
持股股东
持股股东
占比
Panacea Venture
22.05%
He (Wei-Wu)
18.23%
Chen (Zhenfeng)
10.98%
Sparkle Byte Ltd
4.96%
VR Adviser, LLC
4.80%
其他
38.98%
持股股东
持股股东
占比
Panacea Venture
22.05%
He (Wei-Wu)
18.23%
Chen (Zhenfeng)
10.98%
Sparkle Byte Ltd
4.96%
VR Adviser, LLC
4.80%
其他
38.98%
股东类型
持股股东
占比
Venture Capital
31.31%
Individual Investor
29.22%
Corporation
9.39%
Private Equity
4.77%
Research Firm
1.40%
Hedge Fund
1.18%
Investment Advisor
0.44%
Investment Advisor/Hedge Fund
0.09%
其他
22.21%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
45
3.52M
15.33%
--
2025Q3
47
3.52M
15.49%
+359.82K
2025Q2
48
3.16M
23.83%
-498.95K
2025Q1
50
3.66M
24.24%
-92.72K
2024Q4
51
3.58M
28.44%
+88.23K
2024Q3
51
3.49M
21.30%
+239.12K
2024Q2
56
2.52M
16.64%
+1.41M
2024Q1
70
1.11M
17.01%
-1.17M
2023Q4
74
1.13M
12.84%
-66.87K
2023Q3
88
1.20M
16.17%
-105.23K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
He (Wei-Wu)
3.52M
22.69%
+357.64K
+11.33%
Jun 16, 2025
Sparkle Byte Ltd
1.02M
6.58%
--
--
Mar 21, 2025
VR Adviser, LLC
987.26K
6.37%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
787.12K
5.08%
-542.26K
-40.79%
Jun 30, 2025
IDG Capital Partners
915.85K
5.91%
+61.97K
+7.26%
Dec 30, 2024
Wealth Strategy Holding Ltd
908.79K
5.87%
--
--
Mar 21, 2025
BofA Global Research (US)
12.06K
0.08%
+11.99K
+18174.24%
Jun 30, 2025
Woodline Partners LP
165.64K
1.07%
+1.27K
+0.78%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
公告日期
类型
比率
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
May 26, 2022
Merger
10→1
常见问题
CASI Pharmaceuticals Inc的前五大股东是谁？
CASI Pharmaceuticals Inc 的前五大股东如下：
He (Wei-Wu)持有股份：3.52M，占总股份比例：22.69%。
Sparkle Byte Ltd持有股份：1.02M，占总股份比例：6.58%。
VR Adviser, LLC持有股份：987.26K，占总股份比例：6.37%。
Foresite Capital Management, LLC持有股份：787.12K，占总股份比例：5.08%。
IDG Capital Partners持有股份：915.85K，占总股份比例：5.91%。
He (Wei-Wu)持有股份：3.52M，占总股份比例：22.69%。
Sparkle Byte Ltd持有股份：1.02M，占总股份比例：6.58%。
VR Adviser, LLC持有股份：987.26K，占总股份比例：6.37%。
Foresite Capital Management, LLC持有股份：787.12K，占总股份比例：5.08%。
IDG Capital Partners持有股份：915.85K，占总股份比例：5.91%。
CASI Pharmaceuticals Inc的前三大股东类型是什么？
CASI Pharmaceuticals Inc 的前三大股东类型分别是：
Panacea Venture
He (Wei-Wu)
Chen (Zhenfeng)
Panacea Venture
He (Wei-Wu)
Chen (Zhenfeng)
有多少机构持有CASI Pharmaceuticals Inc(CASI)的股份？
截至2025Q4，共有45家机构持有CASI Pharmaceuticals Inc的股份，合计持有的股份价值约为3.52M，占公司总股份的15.33%。与2025Q3相比，机构持股有所增加，增幅为-0.16%。
哪个业务部门对CASI Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对CASI Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
